Which Biotech Companies Are Turning the Tables on Patent Cliffs?
LONDON, January 14, 2013 /PRNewswire/ --
Although much has been made over pharmaceutical company profits tumbling due to loss of exclusivity for blockbuster drugs, companies in the biotechnology technology industry have been turning in strong quarterly earnings, and also have a number of exciting new products that are scheduled to soon hit the market. Companies like Dendreon Corporation (NASDAQ: DNDN), Sequenom Inc. (NASDAQ: SQNM) and Celgene Corporation (NASDAQ: CELG) have been garnering investor attention due to their most recently released financial results, among other things, while Arena Pharmaceuticals Inc. (NASDAQ: PGNX) and Progenics Pharmaceuticals Inc. (NASDAQ: PGNX) have been in the spotlight surrounding progress in bringing new drugs to market. In an attempt to save lives and come out with the next big thing, companies have been focusing their research and development on a number of specific areas, including cancer and obesity. With the research and development costs associated with bringing a new product to market remaining high, companies that are financially sound provide investors with a safer option, as the risk of not having enough capital to complete the process is reduced. See how companies in this industry have grown over the past years and how they are expected to perform in 2013. Talk to our analysts, sign up now for free at
One company that has been performing well from a financial perspective is Dendreon Corp. The company newly announced that preliminary fourth quarter net product revenues are anticipated to come in at $85.5 million, a marked sequential improvement. The company's community accounts also rose in quarter-over-quarter comparisons, with oncology growing 4% and urology jumping 25% overall. Heightened interest for PROVENGE®, the company's autologous cellular immunotherapy for the treatment of prostate cancer, also bodes well for the company moving forward. Find out more about Dendreon Corp. by talking to our financial experts today at
Both Sequenom and Celgene have also been attracting investor attention of late. Sequenom newly posted its Initial 2012 Performance Results, with total revenue of approximately $89 million, an increase of about 59% when compared year-over-year. The life sciences company stated that it saw a strong response to its MaterniT21 Plus test, in part due to a broader acceptance of the test by the OB/GYN physician community. Celgene's unaudited year-over-year 2012 financial results were also impressive. The company stated that total net product sales are expected to be $5.4 billion, an impressive 15% year over year increase. Celgene also saw prosperity out of its REVLIMID offering, as quarterly net product sales in the fourth quarter alone were expected to exceed $1.0 billion. The company has stated that it expects net sales of REVLIMID in 2013 to be between $4.1 billion and $4.2 billion. Get our financial professionals' take on Celgene's latest quarterly earnings by registering at
Elsewhere in the industry, companies have been taking strides to get new products to market. Those that receive FDA approval stand to benefit greatly, and interested investors may want to keep a close eye on how pipeline products are developing for individual companies. Arena Pharmaceuticals has been progressing nicely in this regard, as its anti-obesity product BELVIQ, which has already received FDA approval, is expected by some to launch within the first three months of this year. The potential for the drug is immense given the obesity problem in the U.S. and other nations and the limited number of FDA approved anti-obesity drugs. The company has high hopes for BELVIQ, and recently announced a marketing and supply agreement with Ildong Pharmaceuticals Co. Ltd., by which Ildong will have exclusive rights to market and distribute BELVIQ in South Korea, subject to regulatory approval from the Korea Food and Drug Administration. Progenics has also been active recently, as MedImmune newly stated that it has signed an in-licensing agreement with Progenics for its Clostridium difficile late-stage preclinical program. Is Arena Pharmaceuticals the stock you are planning to add to your portfolio? Check with our analysts if it is a worthy addition by signing up at
With biotechnology firms zeroing in on new treatments and products, the industry looks poised for an exciting 2013. How individual companies will perform will depend on their ability to get new products to market and make existing ones competitive, but for now analysts at StockCall.com believe the outlook is positive. If you want to build on this trend, ask our analysts about the industry and the companies mentioned in this article by visiting us and sign up for free as a member at
StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines. Sign up today to talk to our financial analyst at